2.3.1.43: phosphatidylcholine-sterol O-acyltransferase
This is an abbreviated version!
For detailed information about phosphatidylcholine-sterol O-acyltransferase, go to the full flat file.
Word Map on EC 2.3.1.43
-
2.3.1.43
-
lipoprotein
-
hdl
-
apolipoproteins
-
cholesteryl
-
high-density
-
triglyceride
-
esterification
-
apoa-i
-
atherosclerosis
-
lipase
-
esterify
-
low-density
-
coronary
-
cardiovascular
-
hdl-cholesterol
-
unesterified
-
opacity
-
apoproteins
-
hypercholesterolemia
-
corneal
-
discoidal
-
atherogenic
-
subfractions
-
hdl-associated
-
triglyceride-rich
-
apoc-iii
-
postheparin
-
synthesis
-
hyperlipoproteinemia
-
lysolecithin
-
vldl-c
-
tg-rich
-
dimyristoyl
-
antiatherogenic
-
b-containing
-
normolipidemic
-
cholesterol-loaded
-
xanthoma
-
medicine
-
lipoprotein-cholesterol
-
chylomicron
-
acyl-coa:cholesterol
-
lipid-free
-
paraoxonase
-
apob-containing
-
hdl-mediated
-
3hcholesterol
-
drug development
-
lipid-poor
-
hypertriglyceridemia
-
tangier
-
very-low-density
-
non-hdl
- 2.3.1.43
- lipoprotein
- hdl
-
apolipoproteins
-
cholesteryl
-
high-density
- triglyceride
- esterification
- apoa-i
- atherosclerosis
- lipase
-
esterify
-
low-density
- coronary
- cardiovascular
-
hdl-cholesterol
-
unesterified
- opacity
- apoproteins
- hypercholesterolemia
- corneal
-
discoidal
-
atherogenic
-
subfractions
-
hdl-associated
-
triglyceride-rich
- apoc-iii
-
postheparin
- synthesis
- hyperlipoproteinemia
- lysolecithin
-
vldl-c
-
tg-rich
-
dimyristoyl
-
antiatherogenic
-
b-containing
-
normolipidemic
-
cholesterol-loaded
-
xanthoma
- medicine
-
lipoprotein-cholesterol
- chylomicron
-
acyl-coa:cholesterol
-
lipid-free
- paraoxonase
-
apob-containing
-
hdl-mediated
-
3hcholesterol
- drug development
-
lipid-poor
- hypertriglyceridemia
- tangier
-
very-low-density
-
non-hdl
Reaction
Synonyms
acyltransferase, lecithin-cholesterol, cholesterol transacyltransferase, LAT, LCAT, lecithin cholesterol acyl transferase, lecithin cholesterol acyltransferase, lecithin-cholesterol acyl transferase, lecithin-cholesterol acyltransferase, lecithin/cholesterol acyltransferase, lecithin: cholesterol acyltransferase, lecithin:cholesterol acyl-transferase, lecithin:cholesterol acyltransferase, lysolecithin acyltransferase, phospholipid-cholesterol acyltransferase, plasma lecithin-cholesterol acyltransferase, TgLCAT, TGME49_272420
ECTree
Advanced search results
Application
Application on EC 2.3.1.43 - phosphatidylcholine-sterol O-acyltransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
medicine
synthesis
baculovirus-mediated expression of LCAT in mammalian cells as a high-mannose glycoform suitable for deglycosylation by Endo H and its purification to homogeneity and characterization. Treatment of the protein with Endo H results in a recombinant protein product that retains its native form and is suitable for structural determination by X-ray crystallography
drug development
a therapeutic that increases enzyme LCAT activity may promote reverse cholesterol transport and prove beneficial for the treatment of dyslipidaemia and atherosclerosis
drug development
-
rational development of therapeutics to treat enzyme LCAT deficiency, atherosclerosis and acute coronary syndrome
the recombinant enzyme is utilized for enzyme replacement therapy in case of congenital enzyme deficiency
medicine
-
a complementary effect between myristic acid and alpha-linolenic acid that exerts a positive impact on the metabolism of plasma HDL by activating LCAT
medicine
-
carotid artery intima media thickness (IMT) is greater and plasma LCAT activity is higher in subjects with metabolic syndromes compared to control. Similar increases in IMT and LCAT are found in MetS subjects without type 2 diabetes mellitus. In addition, plasma LCAT activity is independently and positively related to insulin resistance, plasma triglycerides, non-HDL cholesterol and HDL cholesterol. LCAT activity may be a marker of subclinical atherosclerosis
medicine
-
haptoglobin from psoriatic patients exhibits decreased activity in binding haemoglobin and inhibiting LCAT
medicine
-
hemoglobine A1c concentration negatively correlates with LCAT activity in type 2 diabetes patients
medicine
-
in patients bearing a homozygous -629CC polymorphism of the cholesteryl ester transfer protein promoter a higher LCAT activity is measured
medicine
-
it is shown that LCAT activity is lower in pregnancy induced hypertension (PIH) and chronic hypertensive (CH) mothers than in normotensive controls. Similar changes are observed in small for gestational age (SGA) newborns of PHI mothers and in SGA newborns of CH mothers when compared to appropriate for gestational age newborns of control mothers (AGA-NC)
medicine
-
the correction of the aberrant HDL phenotypes by treatment with LCAT suggests a potential therapeutic intervention for HDL abnormalities that result from specific mutations in apoA-I
medicine
a therapeutic that increases enzyme LCAT activity may promote reverse cholesterol transport and prove beneficial for the treatment of dyslipidaemia and atherosclerosis
medicine
LCAT activity and phospholipid transfer protein PLTP activity are positively related to various obesity measures and homoeostasis model assessment. LCAT activity is associated with an fatty liver index FLI above 60, independent of type 2 diabetes and metabolic syndrome, the waist/hip ratio, or homoeostasis model assessment. PLTP activity is also associated with an FLI above 60 independent of these variables
medicine
the plasma concentration of the LCAT enzyme significantly decreases during ST-segment-elevation myocardial infarction (STEMI) with a parallel significant reduction in LCAT activity. High-density lipoprotein isolated from STEMI patients progressively lose the capacity to promote NO production by endothelial cells, and the reduction is related to decreased LCAT concentration. In vitro incubation of STEMI patients' plasma with recombinant LCAT restores high-density lipoprotein ability to promote endothelial NO production